The global Sjogren's syndrome market is predicted to develop as a result of an expanding and strong medication pipeline. For instance, according to information published in July 2022 on the Nation Institute of Medicine (NIH), a multicenter phase 3 study is currently underway to evaluate the effectiveness and safety of the drug ianalumab in patients with Sjogren's syndrome. The study's anticipated completion date is March 2026. Throughout the course of the projection period, the market for drugs to treat sjogren's syndrome is anticipated to rise significantly due to increased research and development.
The global Sjogren’s Syndrome Market is estimated to be valued at US$ 234.6 million in 2022 and expected to exhibit a CAGR of 3.5% over the forecast period (2022-2030).
Leading Companies in the Sjogren’s syndrome Industry:
1. Daiichi Sankyo Co Ltd
Daiichi Sankyo Company, Limited, a pharmaceutical company, manufactures and sells pharmaceutical products worldwide. The company was founded in 1899 and is headquartered in Tokyo, Japan.
2. Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products globally from 1887. The company was headquartered in New York, New York. In September, 2022 announced that the U.S. Food and Drug Administration (FDA) approved Sotyktu™ (deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
3. GlaxoSmithKline PLC
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. On May 2020, it was reported that GSK tap experimental arthritis antibody to calm cytokine storm hitting COVID-19 patients.
4. Novartis/MorphoSys
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol.
5. RemeGen
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics. RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.
6. Otsuka Pharmaceutical Co., Ltd.
Otsuka Holdings Co., Ltd. engages in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. Otsuka Pharmaceutical was established in 1964. The company has headquarters situated in Tokyo, Japan. Otsuka Pharmaceutical Co., Ltd. (Otsuka) has finalized a collaborative agreement with Naruto City and Toyota Tsusho Corporation aiming to contribute to realization of a sustainable society through promotion of horizontal "bottle-to-bottle" recycling of PET bottles. The agreement was finalized on February 9, 2023.
7. Bridge Pharma Inc.
BRIDGE PHARMA, Inc is a privately held pharmaceutical Research and Development company, mainly focusing on medications for the treatment of some wide-spread dermal (atopic dermatitis, psoriasis, and pruritis) and pulmonary (asthma and COPD) diseases. The company has headquarters situated in Sarasota, FL, USA.
*Definition- Sjogren's syndrome causes more serious inflammation that affects several organs, including the kidneys, lungs, intestines, or the brain. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, may be recommended by doctors for these patients.
